BMI1 and chronic myelogenous leukemia, BCR-ABL1 positive: At last the recent availability of the PTC-596, a BMI1 inhibitor is now being tried against the ovarian cancer (ClinicalTrials.gov Identifier: NCT03206645) and the possibility to realize further in vitro and in vivo models with cells where BMI1 could be silenced (for example by the CRISPR approach) probably will give us further demonstration about of a possible translation of our pivotal findings in the clinical scenario of the CML.